The Company is a Korea-based company principally engaged in the research and development of medicines and biotherapeutics. The Company develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The Company research and develop therapeutic drug candidates such as Parkinson's disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs). The Company was established on March 14, 2014. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on November 09, 2018.
Headquarters
9F, 189, Seongam-Ro, Mapo-Gu
Seoul; Seoul;
Contact Details: Purchase the Cellivery Therapeutics, Inc. report to view the information.
Website: http://www.cellivery.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service